✉news BusinessRetail first seen 4 d ago, last 17 h ago, peak #13
Candel Therapeutics Shares Dip Despite Positive Prostate Cancer Drug Data
Original: CADL Slips Despite Encouraging Prostate Cancer Drug Data — Retail Believes Stock Is ‘Clearly A Buy And Hold’
Candel Therapeutics (CADL) shares declined even after the company reported encouraging data for its prostate cancer drug candidate. Retail investors are pushing back against the sell-off, with many calling the stock 'clearly a buy and hold' and arguing the market is overlooking the strength of the clinical results. The divergence between the positive data and the falling share price has become the focus of discussion among individual traders tracking the biotech.
Why now: Retail investors are discussing the disconnect between encouraging clinical trial data and the stock's decline.
Rank over time, top of the chart is #1. 5 snapshots from 23 h ago to 17 h ago.
Evidence
- CADL Slips Despite Encouraging Prostate Cancer Drug Data — Retail Believes Stock Is ‘Clearly A Buy And Hold’ · Stocktwits
API: https://socialmediatrends-api.osmike.com/v1/trends/513108